Results
- Showing results for:
- Reset all filters
Search results
-
Journal articleThurgur H, Lynskey M, Schlag AK, et al., 2024,
Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial
, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, Vol: 90, Pages: 1081-1093, ISSN: 0306-5251 -
Journal articleWeiss B, Roseman L, Giribaldi B, et al., 2024,
Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
, INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION, Vol: 22, Pages: 806-841, ISSN: 1557-1874 -
Journal articleLynskey MT, Athanasiou-Fragkouli A, Thurgur H, et al., 2024,
Medicinal cannabis for treating post-traumatic stress disorder and comorbid depression: real-world evidence
, BJPSYCH OPEN, Vol: 10, ISSN: 2056-4724 -
Journal articleVohryzek J, Cabral J, Lord L-D, et al., 2024,
Brain dynamics predictive of response to psilocybin for treatment-resistant depression
, BRAIN COMMUNICATIONS, Vol: 6 -
Journal articleKusudo K, Tani H, Yonezawa K, et al., 2024,
Development of the Japanese version of the Ego-Dissolution Inventory (EDI).
, Neuropsychopharmacol Rep, Vol: 44, Pages: 292-297AIM: Psychedelics have recently gained attention as potential therapeutic agents for various psychiatric disorders. Previous research has highlighted that a diminished sense of self, commonly termed "ego-dissolution" is a pivotal feature of the psychedelic-induced state. While the Ego-Dissolution Inventory (EDI) is a widely acknowledged instrument for measuring this phenomenon, no Japanese version has been available. This study aimed to develop a Japanese version of the EDI. METHODS: We adhered to the "Guidelines for Best Practices in the Translation and Cultural Modification Process for Patient-Reported Outcomes Instruments: Document from the ISPOR Committee on Translation and Cultural Modification" during our translation approach. Two Japanese psychiatrists independently conducted initial translations, and a consolidated version was achieved via mutual agreement. This version was then back-translated to English and assessed by the original authors for consistency. The repetitive modification process was conducted in continuous dialogues with the original authors until they accepted the concluding back-translated version. RESULTS: The finalized, approved back-translated version of the EDI is presented in the accompanying figure. In addition, the authorized Japanese version of the EDI is included in the Appendix. CONCLUSIONS: In this study, we successfully developed the Japanese version of the EDI. This instrument will assist in assessing ego-dissolution experiences associated with psychedelic-assisted therapy among Japanese speakers. Additional studies are necessary to evaluate the reliability and validity of this newly translated instrument.
-
Journal articleGodfrey K, Muthukumaraswamy SD, Stinear CM, et al., 2024,
Resting-state EEG connectivity recorded before and after rTMS treatment in patients with treatment-resistant depression
, PSYCHIATRY RESEARCH-NEUROIMAGING, Vol: 338, ISSN: 0925-4927 -
Journal articleMarrocu A, Kettner H, Weiss B, et al., 2024,
Psychiatric risks for worsened mental health after psychedelic use
, JOURNAL OF PSYCHOPHARMACOLOGY, Vol: 38, Pages: 225-235, ISSN: 0269-8811 -
Journal articleBarba T, Kettner H, Radu C, et al., 2024,
Psychedelics and sexual functioning: a mixed-methods study
, Scientific Reports, Vol: 14, ISSN: 2045-2322Do psychedelics affect sexual functioning postacutely? Anecdotal and qualitative evidence suggests they do, but this has never been formally tested. While sexual functioning and satisfaction are generally regarded as an important aspect of human wellbeing, sexual dysfunction is a common symptom of mental health disorders. It is also a common side effect of selective serotonin reuptake inhibitors (SSRIs), a first line treatment for depression. The aim of the present paper was to investigate the post-acute effects of psychedelics on self-reported sexual functioning, combining data from two independent studies, one large and naturalistic and the other a smaller but controlled clinical trial. Naturalistic use of psychedelics was associated with improvements in several facets of sexual functioning and satisfaction, including improved pleasure and communication during sex, satisfaction with one’s partner and physical appearance. Convergent results were found in a controlled trial of psilocybin therapy versus an SSRI, escitalopram, for depression. In this trial, patients treated with psilocybin reported positive changes in sexual functioning after treatment, while patients treated with escitalopram did not. Despite focusing on different populations and settings, this is the first research study to quantitively investigate the effects of psychedelics on sexual functioning. Results imply a potential positive effect on post-acute sexual functioning and highlight the need for more research on this.
-
Journal articlePalmisano VF, Agnorelli C, Fagiolini A, et al., 2024,
Membrane Permeation of Psychedelic Tryptamines by Dynamic Simulations
, BIOCHEMISTRY, Vol: 63, Pages: 419-428, ISSN: 0006-2960 -
Journal articleTimmermann Slater CB, Zeifman R, Erritzoe D, et al., 2024,
Effects of DMT on mental health outcomes in healthy volunteers
, Scientific Reports, Vol: 14, ISSN: 2045-2322Psilocybin, a serotonergic psychedelic, is being increasingly researched in clinical studies for the treatment of psychiatric disorders. The relatively lengthy duration of oral psilocybin’s acute effects (4–6 h) may have pragmatic and cost-effectiveness limitations. Here, we explored the effects of intravenous (IV) N,N-Dimethyltryptamine (DMT), a closely related, but faster-acting psychedelic intervention, on mental health outcomes in healthy volunteers. Data is reported from two separate analyses: (1) A comparison of mental health-related variables 1 week after 7, 14, 18, and 20 mg of IV DMT versus IV saline placebo (n = 13) and, (2) A prospective dataset assessing effects before versus 2 weeks after 20 mg of IV DMT (n = 17). Mental health outcomes included measures of depression severity (QIDS-SR16), trait anxiety (STAI-T), Neuroticism (NEO-FFI), wellbeing (WHO-5), meaning in life (MLQ), optimism (LOT-R), and gratitude (GQ-6). In both the prospective and placebo-controlled datasets, significant improvements in scores of depression were found 1–2 weeks after DMT administration. Significant reductions in trait Neuroticism were only found for the placebo-controlled sample. Finally, changes in depression and trait anxiety correlated with acute peak experiences (assessed via ‘Oceanic Boundlessness’). While the use of two separate cohorts in pooled analysis limits the generalizability of these correlational findings, these results suggest that DMT may reduce depressive symptomatology by inducing peak experiences. The short half-life of IV DMT and its potential for flexible dosing via controlled infusions makes it an appealing candidate for psychedelic medicine. Further research in clinical samples is needed to corroborate the therapeutic potential of DMT.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.
